- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT04276558
REC 0/0559 Oční kapky pro léčbu středně těžké a těžké neurotrofické keratitidy u dospělých pacientů
Účinnost, bezpečnost a farmakokinetika 3 dávek očních kapek REC 0/0559 pro léčbu neurotrofické keratitidy stadia 2 (střední) a 3 (těžké) u dospělých pacientů
A phase 2 study, aiming to evaluate the efficacy, safety and pharmacokinetics of REC 0/0559 in treatment of Neurotrophic Keratitis in Adult Patient in Europe and United States of America.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
This was a Phase 2, international, multicentre, dose-ranging, double-masked, randomised, parallel-group, vehicle-controlled study designed to evaluate 3 different doses of REC 0/0559 vs vehicle in patients with Stage 2 and Stage 3 neurotrophic keratitis (NK).
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
-
Dijon, Francie, 21000
- Dijon University Hospital CHU Dijon
-
Paris, Francie
- Hôpital Fondation Adolphe de Rothschild
-
Paris, Francie, 75014
- CHU Paris Centre - Hôpital Cochin
-
Paris, Francie
- Hôpital Universitaire Necker
-
-
-
-
-
Bari, Itálie, 70124
- Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari Clinica Oculistica
-
Bologna, Itálie, 40138
- DIMES Universit di Bologna
-
Florence, Itálie, 50134
- Azienda Ospedaliero-Universitaria Careggi
-
Forlì, Itálie
- Ospedali Privato
-
Genova, Itálie, 16132
- Azienda Ospedaliera Universitaria San Martino
-
Messina, Itálie
- Azienda Ospedaliera Universitaria Policlinico Gaetano Martino
-
Milan, Itálie, 20157
- Ospedale Luigi Sacco
-
Roma, Itálie, 00133
- Fondazione PTV - Policlinico Tor Vergata
-
-
Calabria
-
Germaneto, Calabria, Itálie, 88100
- Università Magna Grecia di Catanzaro
-
-
-
-
-
Budapest, Maďarsko
- Semmelweis University, Dept. of Ophthalmology
-
Pécs, Maďarsko
- University of Pecs - Dpt of Ophthalmology
-
-
Vas County
-
Szombathely, Vas County, Maďarsko, 9700
- Markusovszky University Teaching Hospital
-
-
-
-
-
Cologne, Německo, 50924
- Uniklinik Koeln
-
Düsseldorf, Německo, 40225
- Hospital Eye University of Duesseldorf
-
Frankfurt, Německo, 60590
- Universitaetsklinikum Frankfurt
-
Homburg, Německo
- Saarland University Medical Center
-
Mainz, Německo, 55131
- UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz
-
-
Bavaria
-
Munich, Bavaria, Německo, 80336
- Ludwig-Maximilians-Universitaet Muenchen LMU - Augenklinik
-
-
-
-
-
Glasgow, Spojené království, G75 8RG
- University Hospital Hairmyres
-
London, Spojené království
- Moorfields Eye Hospital NHS Foundation Trust
-
Southampton, Spojené království, SO16 6YD
- Southampton General Hospital
-
-
Mersey
-
Liverpool, Mersey, Spojené království, L7 8XP
- Royal Liverpool University Hospital - St Paul's Clinical Eye Research Centre
-
-
-
-
Florida
-
Crystal River, Florida, Spojené státy, 34429-8722
- Nature Coast Clinical Research
-
Gainesville, Florida, Spojené státy, 32605
- University of Florida
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21201
- University of Maryland School of Medicine UMSOM
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48105
- University of Michigan - Kellogg Eye Center
-
-
New York
-
New York, New York, Spojené státy, 10003
- Mt. Sinai New York Eye and Ear Infirmary
-
-
North Carolina
-
Winston-Salem, North Carolina, Spojené státy, 27157
- Wake Forest Baptist Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Spojené státy, 37215
- Toyos Clinic
-
-
Texas
-
Houston, Texas, Spojené státy, 77025
- Houston Eye Associates HEA - Gramercy Location
-
-
Wisconsin
-
Madison, Wisconsin, Spojené státy, 53705
- University of Wisconsin-Madison
-
-
-
-
-
Barakaldo, Španělsko, 48903
- Hospital de Cruces
-
Barcelona, Španělsko
- Centro de Oftalmologia Barraquer
-
Barcelona, Španělsko, 08035
- Instituto Microcirugia Ocular IMO
-
Madrid, Španělsko, 28040
- Hospital Clinico San Carlos
-
Seville, Španělsko
- Cartuja Vision - Centro de Servicios Oftlamologicos
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, Španělsko, 33012
- Instituto Oftalmologico Fernandez-Vega
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Have read, understood, and signed the informed consent form (ICF).
-
Be a male or female aged ≥18 years at the time of ICF signature.
-
Have stage 2 moderate (PED) or stage 3 severe (corneal ulcer) NK involving only 1 eye (study eye) and of at least 2 weeks duration. Patients with Stage 1 NK in the fellow eye can be enrolled.
for the study eye
-
Have no objective clinical evidence of improvement in the PED or corneal ulceration within the 2 weeks before the screening visit despite use of conventional non-surgical treatment (eg, nonpreserved ocular lubricants, nonpreserved topical antibiotics, oral doxycycline, patching, serum tears, and/or therapeutic contact lenses) as determined by the investigator's or referring physician's medical record.
-
Have decreased corneal sensitivity (≤ 4 cm using the Cochet-Bonnet aesthesiometer) within the area of the PED or corneal ulcer and outside of the area of the defect in at least one corneal quadrant.
-
Have a BCDVA score ≤ 75 ETDRS letters in the study eye, due to NK.
Exclusion Criteria:
-
Have participated in any clinical trial with an investigational drug/device within 2 months before the Screening Visit and throughout the study duration.
-
Have a known hypersensitivity to one of the components of the study drug or procedural medications (eg, fluorescein), including to a compound chemically related to MT8
-
Have a presence or history of any ocular or systemic disorder or condition that might hinder the efficacy of the study treatment or its evaluation, could possibly interfere with the interpretation of study results, or could be judged by the investigator to be incompatible with the study visit schedule or conduct (eg, progressive or degenerative corneal or retinal conditions, lagophthalmos, uveitis, optic neuritis, poorly controlled diabetes, autoimmune disease, systemic infection, neoplastic diseases), or that may compromise the safety of the patient.
-
Have a significant history of alcohol abuse or drug/solvent abuse
-
Be unwilling to comply with any study assessments or procedures.
-
Be a woman who is pregnant, nursing or planning a pregnancy.
-
Be a woman of childbearing potential not using a highly effective method of birth control.
-
Be a male patient who is not permanently sterile and who is not willing to use condoms during the study and for 4 weeks after the end of study treatment.
For the study eye:
-
Have any active ocular infection (bacterial, viral, fungal or protozoal) or active inflammation not related to NK in the study eye.
-
Have any other ocular disease requiring topical ocular treatment in the study eye during the course of the study treatment period, except for glaucoma if treated by preservative-free eye drop (single-agent treatment, once daily, stable regimen 4 weeks before screening and during the study),
-
Receive topical ophthalmological treatments other than the study drug provided by the study Sponsor and the treatments allowed by the study protocol (eg, preservative-free artificial tears; preservative-free eye drop (single-agent treatment, once daily, stable regimen 4 weeks before screening and during the study) for glaucoma; topical antibiotics; other than tetracycline).
-
Have severe blepharitis and/or severe meibomian gland disease in the study eye.
-
Have severe vision loss in the study eye with no potential for visual improvement in the opinion of the investigator as a result of the study treatment.
-
Have evidence of corneal ulceration/melting involving the posterior third of the corneal stroma, or perforation in the study eye.
-
Have a history of any ocular surgery (including laser or refractive surgical procedures) within 3 months before the Screening Visit in the study eye. An exception to the preceding statement will be allowed if the ocular surgery is considered to be the cause of the Stage 2 or 3 NK.
-
Have a history of corneal transplantation in the study eye, except if performed to treat NK and at least 6 months prior screening.
-
Have had prior surgical procedures for the treatment of NK (eg, tarsorrhaphy, conjunctival flap, etc.) except AMT, if at least 2 wks after the membrane has disappeared within the area of the PED or corneal ulcer (and at least 6 weeks after the procedure) in the study eye.
-
Use therapeutic contact lenses or wear contact lenses for refractive correction during the study treatment periods in the eye(s) with NK.
-
Have an anticipated need for punctal occlusion during the study treatment period. Patients with punctal occlusion or punctal plugs inserted before the study are eligible for enrolment provided that the punctal occlusion is maintained during the study.
-
Have an uncontrolled glaucoma at the Screening Visit. (Patients suffering from glaucoma requiring ophthalmic drops for topical treatment at the Screening Visit or during the study are not eligible, except if the ophthalmic drops is a preservative-free treatment administered maximum once daily as a single-agent treatment and at a stable regimen 4 weeks before screening and at the same dose during the study. Patients treated with oral intraocular pressure-lowering drugs at the Screening Visit and during the study may be enrolled if their glaucoma status is assessed as stable and controlled.
For the fellow eye
-
Have Stage 2 or 3 NK or perforation.
For any eye:
-
Have a history of ocular cancer.
-
Have had prior treatment with Oxervate™
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Sekvenční přiřazení
- Maskování: Trojnásobný
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Dose 1 - 0.5 µg/day
Dose of study drug per day: 0.5 µg/day Study drug concentration: 5 µg/mL MT8 given 1 drop QID |
Eye drop solution in single dose unit.
Ostatní jména:
Eye drop solution with no active substance in single dose unit. |
|
Experimentální: Dose 2 - 2.5 µg/day
Dose of study drug per day: 2.5 µg/day Study drug concentration: 25 µg/mL MT8 given 1 drop QID |
Eye drop solution in single dose unit.
Ostatní jména:
Eye drop solution with no active substance in single dose unit. |
|
Experimentální: Dose 3 - 5 µg/day
Dose of study drug per day: 5 µg/day Study drug concentration: 50 µg/mL MT8 given 1 drop QID |
Eye drop solution in single dose unit.
Ostatní jména:
Eye drop solution with no active substance in single dose unit. |
|
Komparátor placeba: Vehicle
Dose of study drug per day: 0 µg/day Study drug concentration: Vehicle given 1 drop QID |
Eye drop solution with no active substance in single dose unit. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Corneal Healing
Časové okno: At week 8
|
The primary endpoint of this study is the percentage of patients achieving complete corneal healing of PED or corneal ulcer at Week 8, defined as no corneal fluorescein staining in the area of the PED or corneal ulcer as assessed by an independent central reading centre. |
At week 8
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Visual Acuity
Časové okno: At week 8
|
Percentage of patients who achieve a 5-, 10-, and 15-letter mean improvement in best corrected distance visual acuity (BCDVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) chart at Week 8 compared to baseline (in all patients and in patients with a central location of the PED or corneal ulcer, respectively). |
At week 8
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další identifikační čísla studie
- REC0559-B-001
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .